Litcius/Paper detail

The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma

Shuaishuai Zhang, Weiwei Gao, Juan Tang, Huaifang Zhang, Yuqi Zhou, Jie Liu, Kun Chen, Fangzhou Liu, Wengang Li, Sally K. Y. To, Alice S.T. Wong, Xiao-kun Zhang, Hu Zhou, Jin-Zhang Zeng

2020Theranostics31 citationsDOIOpen Access PDF

Abstract

: Our findings demonstrate that GSK-3β is a disruptor of retinoid signalling and a new resistant factor of sorafenib in HCC. Targeting GSK-3β may be a promising strategy for HCC treatment in clinic.

Topics & Concepts

SorafenibHepatocellular carcinomaCancer researchRetinoidSignal transductionMedicineInternal medicineOncologyChemistryPharmacologyBiologyCell biologyRetinoic acidBiochemistryGeneCancer, Lipids, and MetabolismCancer Mechanisms and TherapyFerroptosis and cancer prognosis
The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma | Litcius